CLINICAL STUDY OF AT-2266
スポンサーリンク
概要
- 論文の詳細を見る
A clinical study of AT-2266, a new pyridonecarboxylic acid derivative, was performed in the field of internal medicine.<BR>Three inpatients and 2 outpatients, or a total of 5 patients were admitted to the study. The diseases under study were classified as 3 cases of urinary tract infection (2 cases of acute pyelonephritis and 1 case of chronic cystitis) and 2 cases of chronic bronchitis.<BR>The causative organism was <I>E. coil</I> or <I>P. inconstans</I> in urinary tract infections and <I>H. influenzae</I> in chronic bronchitis.<BR>The drug was administered in doses of 200 mg three times daily for 6 -12 days.<BR>The clinical response was excellent in 2 cases and good in 1 case for urinary tract infection and excellent in 1 case and fair in 1 case for chronic bronchitis.<BR>No particular side effects were encountered. As for clinical laboratory findings, moderately elevated GOT, GPT and Al-p were found in 2 cases, but the causal relationship with this drug was unknown.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.